Skip to Content
Merck

GF09165786

Lanthanum

foil, 25x25mm, thickness 0.1mm, as rolled, 99%

Synonym(s):

Lanthanum, LA000210

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
La
CAS Number:
Molecular Weight:
138.91
NACRES:
NA.23
PubChem Substance ID:
UNSPSC Code:
12141607
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥99%

form

foil

manufacturer/tradename

Goodfellow 091-657-86

resistivity

54 μΩ-cm

bp

3464 °C (lit.)

mp

920 °C (lit.)

density

6.19 g/mL at 25 °C (lit.)

SMILES string

[La]

InChI

1S/La

InChI key

FZLIPJUXYLNCLC-UHFFFAOYSA-N

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow


Still not finding the right product?

Explore all of our products under Lanthanum


Storage Class

4.3 - Hazardous materials which set free flammable gases upon contact with water

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Stuart M Sprague
Current medical research and opinion, 23(12), 3167-3175 (2007-11-10)
Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate. A literature search was performed
Gadolinium and lanthanum: a iatrogenic transmetallation?
Simona Brambilla et al.
Clinical biochemistry, 41(13), 1029-1033 (2008-06-19)
Stephen J P Damment et al.
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk